Public Affairs Director Michael Capuano appeared on WGBH to comment on Super Tuesday. Capuano noted that changes in polling following one state’s primary often reflect a change in feeling rather than voting. “It’s pretty well known that a lot of people have been looking at this for a long time and haven’t really decided who they are going to vote for,” he said.
Capuano served as the U. S. Representative for Massachusetts’ 7th Congressional District from 1999 to 2019. He was a senior member of the Transportation and Infrastructure Committee and the Financial Services Committee, and chair of the Special Task Force on Ethics Enforcement, which resulted in the establishment of the Office of Congressional Ethics
Watch Capuano’s Super Tuesday commentary here, or listen here.
Capuano served as the U. S. Representative for Massachusetts’ 7th Congressional District from 1999 to 2019. He was a senior member of the Transportation and Infrastructure Committee and the Financial Services Committee, and chair of the Special Task Force on Ethics Enforcement, which resulted in the establishment of the Office of Congressional Ethics
Watch Capuano’s Super Tuesday commentary here, or listen here.
Related News
September 18, 2026
In the News
Patrick Daugherty Authors Article on Navigating Proposed SEC Crypto Asset Regulations
Foley & Lardner LLP partner Patrick Daugherty authored the Columbia Law School’s Blue Sky Blog article, “How to Advise Token Developers in Light of Proposed SEC Regulation Crypto Assets.”
September 17, 2026
In the News
Foley Featured in Law.com for Guiding Kontoor Brands in Sale of Lee®
Foley & Lardner LLP partner Bryan Schultz is featured for leading the Foley deal team which advised Kontoor Brands in the sale of its Lee® business in Law.com's “How the Deal Got Done” series.
September 15, 2026
In the News
David Rosen Shares Insights on FDA Efforts to Accelerate Human Clinical Trials
Foley & Lardner LLP partner David Rosen shared insights in the recent Law360 article, “FDA Seeks Applications For Project To Speed Up Human Trials,” on the FDA's pilot program pairing pharmaceutical companies with research institutions to accelerate human clinical trials.